Homology Medicines (LTS:0T6G) Other Net Income (Loss) : $-25.88 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Other Net Income (Loss)?

Homology Medicines's Other Net Income (Loss) for the three months ended in Dec. 2023 was $-13.96 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.88 Mil.

Homology Medicines's quarterly Other Net Income (Loss) increased from Jun. 2023 ($-5.74 Mil) to Sep. 2023 ($-3.38 Mil) but then declined from Sep. 2023 ($-3.38 Mil) to Dec. 2023 ($-13.96 Mil).

Homology Medicines's annual Other Net Income (Loss) declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-5.49 Mil) and declined from Dec. 2022 ($-5.49 Mil) to Dec. 2023 ($-25.88 Mil).

Homology Medicines Other Net Income (Loss) Historical Data

The historical data trend for Homology Medicines's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Other Net Income (Loss) Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

-5.49

-25.88

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-1.36	-2.80	-5.74	-3.38	-13.96

Homology Medicines Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.88 Mil.

Homology Medicines Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (LTS:0T6G) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (LTS:0T6G) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

FIXX:USA 35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (LTS:0T6G) Headlines

No Headlines